Skip to main content
Fig. 2 | Cell & Bioscience

Fig. 2

From: Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells

Fig. 2

Characteristics of novel constructed oncolytic adenovirus. a, b Recombinant oncolytic adenovirus (MOI = 40) does not infect microglial HMC3 and BV2 cells (×50, scale bars = 1000 µm). c The capacity of recombinant oncolytic adenovirus to infect GBM cells. Representative photomicrographs were obtained from GL261, U251, U87, and primary cells BT-01 that treated with Ad5-GFP and Ad5-Ki67/GFP at an MOI of 40 for 72 h (×50, scale bars = 1000 µm). d Quantification of the average intensity difference in GBM cells treated with Ad5-GFP and Ad5-Ki67/GFP for 72 h using Image Pro Plus. (n ≥ 3) *P < 0.05 and **P < 0.01. ***P < 0.001 and ****P < 0.0001

Back to article page